ライフサイエンスコーパス: blood donor

1 lood count [CBC]), and 102 controls (healthy blood donors).

2 ified the 25P13 antibody from an independent blood donor.

3 ration of more than 10(9) IPCs from a single blood donor.

4 n ex vivo from an EBV seropositive unrelated blood donor.

5 ftment after a second transfer from the same blood donor.

6 was detected in peripheral blood of healthy blood donors.

7 tients with osteomyelitis and in 299 matched blood donors.

8 ich were coinfected with HCV, and 54 healthy blood donors.

9 nfected or HIV-1/HCV coinfected patients, or blood donors.

10 recently infected vs more remotely infected blood donors.

11 by blood centers to improve safety for young blood donors.

12 ymorphism (SNP) profile of healthy AA and EA blood donors.

13 d with only 3 of 44 (6.8%) healthy volunteer blood donors.

14 rols were derived from 1280 northern English blood donors.

15 be assessed by follow-up studies of viremic blood donors.

16 lidation, we analyzed plasma samples from 79 blood donors.

17 ro generated monocyte-derived DCs of healthy blood donors.

18 ute zoster and in 9% of healthy asymptomatic blood donors.

19 ith neurologic symptoms and 44% of voluntary blood donors.

20 screening of plasma samples from individual blood donors.

21 exposure to the virus in many indeterminate blood donors.

22 es 1, 2, and 5 in samples from South African blood donors.

23 to WNV and to identify potentially infected blood donors.

24 blood mononuclear cells (PBMCs) from healthy blood donors.

25 er among tissue donors than among first-time blood donors.

26 d 5 with arthritis), and sera from 20 normal blood donors.

27 ined by testing 999 specimens from volunteer blood donors.

28 ns was lower in Ghanaian than United Kingdom blood donors.

29 loped for race differentiation of peripheral blood donors.

30 ver diseases (339 with hepatitis C) and 2380 blood donors.

31 m a frozen bank of CTLs derived from healthy blood donors.

32 to 2.17) to be anti-HEV positive than normal blood donors.

33 a 15% prevalence of chronic HBV infection in blood donors.

34 higher risk of HEV infection than are normal blood donors.

35 body-negative acute infection among low-risk blood donors.

36 overcome to successfully mobilise volunteer blood donors.

37 cancer patients over control antibodies from blood donors.

38 -1C-specific CTL responses of HIV-1-infected blood donors.

39 ients referred for evaluation and 70 healthy blood donors.

40 ssion of hepatitis C virus (HCV) by specific blood donors.

41 ults were positive for 5 of 19 (26%) healthy blood donors.

42 munities and 5559 (81.4%, 80.4-82.3) of 6832 blood donors.

43 ls in communities and 721 (13.0%, 12.1-13.9) blood donors.

44 patitis C virus epitope in a random group of blood donors.

45 d Kingdom and Vietnam and from 26 healthy US blood donors.

46 identify 16 invariant TCRs shared among many blood donors.

47 V RNA-negative plasma and PBMCs from healthy blood donors.

48 n a control group of 41 age- and sex-matched blood donors.

49 rroborating with those obtained from healthy blood donors.

50 anti-PEG antibodies in a quarter of healthy blood donors.

51 f antibody responses in 370 WNV-seropositive blood donors.

52 patients with IBD and 112 healthy unrelated blood donors.

53 ith CD, 25 patients with UC and 45 controls, blood donors.

54 widespread in the English population and in blood donors.

55 CRC patients was compared with 5270 healthy blood donors.

56 to be damaging and not found among 185 local blood donors.

57 e unequivocal identification of Vel-negative blood donors.

58 ence interval [95% CI], 0.0025 to 0.007) for blood donors, 0.86 (95% CI, 0.02 to 0.71) for VA patient

59 land Medical System, 1,010 samples from U.S. blood donors, 1,141 samples from patients in a high-inci

60 ietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated don

61 disease (n = 106) and 2 control groups (198 blood donors, 151 patients with Crohn's disease) were an

62 We prospectively recalled 363 past blood donors (180 who were rapid screen assay [RSA] posi

63 selected comparative group of United Kingdom blood donors (2.5 x 10(5) versus 2.9 x 10(6) IU/ml; P =

64 tients with early RA, 2 (2.7%) of 73 healthy blood donors, 2 (2.1%) of 94 individuals with osteoarthr

65 45 263 whole blood donors (22 466 men, 22 797 women) were recruited b

66 as 20%-significantly higher than that of 177 blood donors (5.1%; P=.001; OR, 4.67; 95% CI, 1.91-11.65

67 he Asp299Gly polymorphism was 5.9% among 879 blood donors, 6.5% among 1047 patients with microbiologi

68 also from the blood of 9 of 15 HCV-negative blood donors (60%), while a second HCV NS3 determinant w

69 HV-8 seroprevalence was 2.8% (29/1023) among blood donors, 7.1% (96/1350) among transfusion recipient

70 The effect of blood donor adverse events on donor retention rates is a

71 ive kidney transplant recipients and healthy blood donors after stimulation of peripheral blood monon

72 ELISpot frequencies from healthy HPV-exposed blood donors against HLA-A*0201-binding peptides were un

73 gmatic, randomised trial, we recruited whole blood donors aged 18 years or older from 25 centres acro

74 asles seroprevalence survey of 508 Minnesota blood donors aged 20-39 years was conducted; 91% had ser

75 to infection, from a single sample of 1,936 blood donors aged 20-70 years in mainland France in June

76 initially asymptomatic T cruzi-seropositive blood donors, although disease was mild at diagnosis.

77 V prevalence in both swine veterinarians and blood donors among the eight selected states, with subje

78 Mononuclear cells from 56 blood donors and 10 livers that were not suitable for tr

79 Eighteen (11.3%) of the blood donors and 11 (5.1%) of the B. burgdorferi-seroneg

80 ggregated IgG (H-IgG) (control) in 15 normal blood donors and 16 RA patients not receiving immunosupp

81 case-control study of 2,316 HCV-seropositive blood donors and 2,316 seronegative donors matched on ag

82 The groups included 159 adult blood donors and 215 children who were seronegative for

83 nses against clinically relevant TAAs in 114 blood donors and 44 women during their first pregnancy.

84 a antagonist and that only 2% to 5% of human blood donors and 5% of chimpanzees present with pre-exis

85 As healthy controls 160 adult blood donors and 65 children were included.

86 eactivity with serum samples from 95 healthy blood donors and 94 human immunodeficiency virus (HIV)-i

87 on of HLA antibodies in plasma of implicated blood donors and a combination of the granulocyte agglut

88 Arg296 was found in 6 other primates, > 250 blood donors and A(pae) family relatives without the A(p

89 e western United States, and the movement of blood donors and donated blood components may result in

90 A review of blood donors and follow-up testing identified one donor

91 tested serum and plasma samples from healthy blood donors and from patients with blood cultures posit

92 S. aureus isolates (n = 334) from healthy blood donors and from patients with invasive disease wer

93 quencing analysis in 26 libraries from three blood donors and negative controls.

94 nes from HLA-A*0201-positive (HLA-A*0201(+)) blood donors and patients with myeloma.

95 il-specific antibodies in the plasma of both blood donors and recipients have been implicated in the

96 newly generated viral genome sequences from blood donors and recipients, we assess the dynamics of d

97 dengue RNA detection period in asymptomatic blood donors and relationships between donor viremia and

98 ositive (30 with HTLV-I and 55 with HTLV-II) blood donors and their stable (>or=6 months) heterosexua

99 antly elevated in ICU patients compared with blood donors and were the highest in septic patients.

100 ally screened in 4,984 samples from Ghanaian blood donors, and 1.3% prevalence was found.

101 West Nile fever, 17 West Nile virus-positive blood donors, and 19 deaths in 2012.

102 region located in SMIM1 intron 2 in Swedish blood donors, and observed a strong correlation between

103 , determinants and importance of low iron in blood donors, and on the efforts to reduce or prevent ir

104 ound in any of 100 randomly selected healthy blood donors, and only 2 of 23 patients receiving tirofi

105 ected information and blood samples from all blood donors, and pretransfusion samples were collected

106 ed from naive T cells, purified from healthy blood donors, and reactivated in the presence of IL-1bet

107 celiac disease patients' sera versus normal blood donors, and their conformational features were eva

108 m veterinarians, U.S. and non-U.S. volunteer blood donors, and U.S. and non-U.S. animal handlers.

109 Among 653 healthy volunteers, blood donors, and women on delivery, high-titered HLA-A*

110 mutation ascertained by genetic screening of blood donors; and patients presenting clinically with ha

111 One in 200 blood donors are heterozygous for the TACI A181E mutatio

112 +/- 0.1% of CD34(+) cells from healthy adult blood donors are positive for VEGFR-3.

113 Blood donors are routinely screened for hepatitis C viru

114 cer) study (July 2008-October 2012) plus 312 blood donors as healthy participants.

115 mary human macrophages derived from the same blood donors as the monocytes.

116 performed a large, cross-sectional study of blood donors at 6 US blood centers during 2006-2007.

117 ge-scale genotyping for HNA-3a/b to identify blood donors at risk to have HNA-3a-specific antibodies

118 The test was also offered to potential blood donors attending the central hospital in the capit

119 ion of genetic and epidemiological data from blood donor banks may be useful to anticipate epidemic s

120 establishing a 100% voluntary nonremunerated blood donor base and implementing component therapy.

121 PBMCs from 2 healthy HCV-negative blood donors became HCV RNA positive, with B-cell predom

122 tained intermittently from healthy HLA-typed blood donors between 1999 and 2012, we were able to demo

123 lar, and WHO reports using the search terms "blood donor", "blood donation","blood safety", "blood ba

124 lood donor spleen inoculum compared with the blood donor brain inoculum, suggesting lower titres of i

125 ear cells were isolated from 27 non-selected blood donor buffy coats, and ILCs were sorted by FACS.

126 ntenatal clinic groups, 1.99% (1.86-2.12) in blood donors, but 6.9% (6.1-7.5) in other general popula

127 HTLV-2 are prevalent at low levels among US blood donors, but recent data on their prevalence is lac

128 positive and 328 HTLV-II-seropositive former blood donors, by use of real-time polymerase chain react

129 Information about the implicated blood donors came from the National Malaria Surveillance

130 ted through large-scale routine screening of blood donors can complement molecular surveillance studi

131 Although the risk to blood donors cannot be eliminated, a systematic approach

132 ate that a significant percentage of healthy blood donors carry Chlamydia pneumoniae in their blood.

133 atic advances in blood banking in the 1970s, blood donor centers began supplying hospitals with indiv

134 recipients' marrow function was normal, and blood-donor chimerism levels were 97% to 100%.

135 gically suppressed patients or to 13 healthy blood donors, circulating CD141 (BDCA-3)(+) and CD1c (BD

136 and 1996 and in fresh PBMCs from 19 healthy blood donors collected in 2002 to 2003.

137 and injury occurs among 16- and 17-year-old blood donors compared with older donors.

138 with newly diagnosed type 1 diabetes and 50 blood donor control subjects, together with the WHO refe

139 derived from data on 200 RA patients and 98 blood donor controls, in which positivity for >/=9 ACPAs

140 (-511) and IL1RN(+2018) loci of patients and blood donor controls.

141 ween patients with meningococcal disease and blood donor controls.

142 nts with chronic HCV infection or uninfected blood donors (controls); NK cells and monocytes were iso

143 Using American Red Cross blood donor data as an example, the authors found that i

144 Of 39 134 recruited blood donors, DENV-4 viremia was confirmed in 0.51% of d

145 ailable self-Ag and the genetics of the cord blood donor dictate the levels of central tolerance and

146 An understanding of characteristics of blood donors donating in times of crisis may help predic

147 pitation studies in macrophages from control blood donors (donor) and patients with either FPN1 p.A77

148 ppressive activity ex vivo as 54% of healthy blood donors examined had fully suppressive Tregs sponta

149 Testing of blood donors for human immunodeficiency virus type 1 (HI

150 .S. swine veterinarians) and 400 normal U.S. blood donors for immunoglobulin G anti-HEV.

151 Policies recommend screening blood donors for malaria, but none of the commonly used

152 tests of "minipools" of 16 samples to screen blood donors for West Nile virus RNA began in July 2003.

153 ), extracted from the plasma of thousands of blood donors, for removing HLA antibodies (Abs) in highl

154 ed, HCV antibody-positive (HCV+), allogeneic blood donors from 1991 to 2002 and 10,259 HCV antibody-n

155 ropositive, and 799 HTLV-seronegative former blood donors from 5 U.S. blood centers for a median of 1

156 tude, we identified HBV chronically infected blood donors from a major hospital in Ghana with a range

157 from the United States, and 4 (19.0%) of 21 blood donors from Italy.

158 The study of 61 HBV carrier blood donors from Lebanon revealed multiple patterns of

159 from a total of 600 American Red Cross adult blood donors from six locations in 2010.

160 In contrast, 18% of the blood donors from the same eight U.S. states were positi

161 imens from 30 transfusion recipients and 120 blood donors from the Transfusion-Transmitted Viruses St

162 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21

163 IgA-deficient individuals than among healthy blood donors (GMT, 90.9) (P < 0.0001).

164 Only 40 (24%) of 165 relatives of blood donors had been tested.

165 Cord-blood donors had normal alpha-L-iduronidase activity (me

166 No Babesia test for screening blood donors has been licensed.

167 in donated blood, but no systematic study of blood donors has been reported.

168 The HTLV-1 and HTLV-2 prevalences among US blood donors has declined since the early 1990s.

169 ught to affirm that T. cruzi-seropositive US blood donors have persistent infection with demonstrable

170 ients (UGT1A1*28 homozygous) and 249 healthy blood donors (HBD) were genotyped for UGT1A (UGT1A1*28,

171 tcome of infection among 115 WNV-positive US blood donors identified in 2008-2011.

172 comparing CCR5Delta32 distribution among US blood donors identified through a comprehensive blood su

173 Nile virus (WNV) infection, acutely viremic blood donors, identified by nucleic acid amplification t

174 we utilized samples collected from volunteer blood donors in 17 provinces and municipalities.

175 Data on all first-time blood donors in a large network of US blood centers were

176 eptides in 81% of HIV-1- or HIV-1/2-infected blood donors in Abidjan, Cote d'Ivoire.

177 en analyzed with cells from EBV-seronegative blood donors in culture.

178 Blood donors in Denmark and Sweden between 1987 and 2012

179 h malaria parasites are commonly detected in blood donors in malaria-endemic areas, transfusion-trans

180 In human blood donors in Nicaragua, we observed a striking domina

181 data were compared with those of first-time blood donors in order to generate estimated incidence ra

182 ucing the antibody negative window period in blood donors in resource limited settings where nucleic

183 eptide-specific, CD8(+) T cells from healthy blood donors in vitro and capable of recognizing and lys

184 less frequent (2 of 14 patients [14.2%]) in blood donors in whom WNV infection was identified by WNV

185 Selected units were sourced from blood donors included in the British Bone Marrow Registr

186 d increase in overall mortality among former blood donors, including significantly increased mortalit

187 ort for the first time an asymptomatic human blood donor infected with B. clarridgeiae, as documented

188 The detection of hepatitis B virus (HBV) in blood donors is achieved by screening for hepatitis B su

189 re on how to find, recruit and maintain rare blood donors is not overwhelming, there are quite a few

190 sidered to be relatively low, and testing of blood donors is often not done or is done relatively poo

191 ections in the English population (including blood donors) is unknown, but is probably widespread, an

192 vian Donations and Transfusions) database of blood donors linked with other nationwide health data re

193 globulin G (IgG) and IgM among 10,569 French blood donors living in mainland France and three oversea

194 tive cause) were investigated for peripheral blood donor lymphocyte macrochimerism.

195 ntravenous gamma globulin (n = 13) or normal blood donors (n = 20).

196 and sera obtained from healthy, HBV-negative blood donors (n = 20).

197 the assay, serum samples were assembled from blood donors (n = 372), acute hepatitis E patients (n =

198 -seropositive healthy adults but not in cord blood donors (n = 5).

199 in two animal facilities and age/sex-matched blood donors (n = 63) as controls were tested for IgG an

200 udy, HIV patients (n = 457) and HIV-negative blood donors (n = 79) presenting to an HIV clinic in Gha

201 1E-heterozygous than TACI-sufficient Swedish blood donors never immunized with pneumococcal antigens.

202 In this healthy population of blood donors, non-O blood groups explain >30% of venous

203 3.1% among personnel compared to 3.2% among blood donors; none were positive for IgM anti-HEV or HEV

204 es sampled from four self-limited cases, one blood donor, one fatal adult case, and one newborn with

205 n Europe may not optimize the gifts of whole-blood donors or minimize healthcare costs.

206 ted compared to 6.4% (16/250) observed among blood donors (OR, 1.3; CI, 0.41 to 4.0; P = 0.43).

207 rates were not elevated compared to those of blood donors (OR, 2.0; 95% CI, 0.10 to 122.9; P = 0.50).

208 ransplant recipients and 1 of 24 (4%) normal blood donors (p < or = 0.001).

209 was low, 4.0% (2/50), and similar to that of blood donors (P = 0.46; odds ratio [OR], 1.4; confidence

210 ancer patients and not with sera from normal blood donors: p53, MAGEA3, SSX2, NY-ESO-1, HDAC5, MBD2,

211 (HCV) infection due to large numbers of paid blood donors (PBD), injection drug users (IDU), and sexu

212 Blood donor plasma viremia status was first determined w

213 ymized samples were representative of the US blood donor population (n = 5000), healthy UK donors (n

214 rt of 64 individuals selected from a healthy blood donor population.

215 Targeting blood donor populations most likely to have influenza in

216 H1N1 influenza viremia (via RNA testing) in blood donor populations using multiple sensitive detecti

217 In blood donors, primary immune responses of low and/or hig

218 Leukocytes of P-negative blood donors produced higher levels of TNF-alpha than th

219 undant evidence that leukocyte antibodies in blood donor products are somehow involved in transfusion

220 Nucleic acid testing (NAT) of blood donors provides opportunities for identifying West

221 Observations of MBL in blood donors raise concern that transmitted MBL may caus

222 Only one-third of the healthy blood donors reactive by IFA were confirmed to be positi

223 ope mismatches and pretransplant, peripheral blood, donor-reactive IFN-gamma ELISPOT assay results co

224 and subsequently addressed through improved blood donor recruitment programs.

225 Of blood donors reporting ILI symptoms postdonation, 1 of 1

226 healthy middle-aged and eight healthy older blood donors representing an average age difference of a

227 dependence on recruiting and retaining young blood donors requires a committed approach to donor safe

228 itch regions of memory B cells from European blood donors revealed frequent templated inserts origina

229 In 130 blood donors sampled during 2012 in Jeddah and 226 slaug

230 E1 and/or NS5B sequences from 411 volunteer blood donors sampled in 17 provinces and municipalities

231 ctivity to 15 other viruses tested or to 420 blood donor samples from the WNV pre-epidemic season.

232 rth Carolina, and Alabama) from which normal blood donor samples were available, 26% were positive wi

233 Improvements in blood donor screening have decreased transfusion-associa

234 ly detect XMRV/MLV in blood samples and that blood donor screening is not warranted.

235 ing of blood from non-outbreak areas until a blood donor screening test becomes available have been i

236 IV-1) and hepatitis C virus (HCV) RNA during blood donor screening.

237 Blood donor sera were assayed for HSV-2 antibodies by bo

238 ch were found both in meningioma and healthy blood donor sera.

239 human CTL line from a normal healthy HLA-B7+ blood donor specific for this peptide.

240 mice that were pretreated with C57BL/6 (B.6) blood (donor-specific transfusion, DST) and nondepleting

241 and three received hu5C8 combined with whole blood donor-specific transfusion (DST).

242 onger incubation times were observed for the blood donor spleen inoculum compared with the blood dono

243 Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age

244 ut none of the 30 serum samples from healthy blood donors, suggesting its potential application as an

245 t with 30 control serum samples from healthy blood donors, suggesting their potential application for

246 EV between the at-risk group and age-matched blood donors suggests low transmission risk with univers

247 specific responses in 15 of 30 indeterminate blood donors tested, compared with none in controls (p=0

248 xposed individuals, but none of the European blood donors tested, have high levels of LAIR1-containin

249 rol subjects), 67% (8 patients and 4 healthy blood donors) tested positive for C pneumoniae-specific

250 conclusion, MBL prevalence is much higher in blood donors than previously reported, and although unco

251 raries was obtained from 12 HUE cases and 26 blood donors; the remaining HUE cases were sequenced as

252 cytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttra

253 l population of 240 North American white NIH blood donors typed for HLA antigens by the same molecula

254 revention diagnostic criteria and 50 healthy blood donors, using a microarray with a cutoff fold diff

255 ed in 55 patients with CFS/ME and 75 healthy blood donors, using quantitative polymerase chain reacti

256 ca, the prevalence of malaria parasitemia in blood donors varies from 0.6% to 50%.

257 m four populations with various risks, i.e., blood donors, Veterans Administration (VA) patients, you

258 In parallel, genomic DNA from the blood donor was amplified to generate the late proviral

259 al after receipt of a transplant from a cord-blood donor was at least as favorable as that after rece

260 C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the pre

261 The prevalence of HIV among blood donors was 6.4% (120 of 1877) and varied by hospit

262 prevalence in swine veterinarians and normal blood donors was age specific and paralleled increasing

263 on of healthy United States Caucasian random blood donors was in Hardy-Weinberg equilibrium and CCR5D

264 The T-cell response of these healthy blood donors was mediated by memory T cells, which cross

265 Viral genetic variant distribution in blood donors was similar to that seen in high-risk US po

266 Plasma from healthy blood donors was tested by enzyme-linked immunosorbent a

267 Cord blood donors were 40 women, ages >/=18 years, who delive

268 All 36 blood donors were BG negative, and 13 of 15 candidemic p

269 Buffy coats from blood donors were examined for inflammatory responses to

270 generated in vitro from the same individual blood donors were exposed to 5 different pathogens, and

271 he TNFRII 196 M/R polymorphism, 79 volunteer blood donors were genotyped at this locus, by polymerase

272 reported for specimens from 50 seronegative blood donors were negative at all three specimen input v

273 All healthy blood donors were negative for XMRV proviral sequences.

274 ed from differentiating erythroid cells from blood donors were performed to determine the transcripti

275 Eight patients and three blood donors were positive mostly for two subgroups of t

276 74 patients with colon cancer and 75 normal blood donors were screened for antibody reactivity to 77

277 nonuclear cells (PBMCs) from 35 WNV-infected blood donors were screened for virus-specific T cell res

278 lood mononuclear cells from 44 healthy human blood donors were tested for reactivity against HLA-matc

279 PBMC from 69 aviremic and 56 viremic blood donors were then analyzed for the presence of HCV

280 d 25-OH vitamin D were measured; 119 healthy blood donors were used as controls.

281 from HBsAg-seropositive patients and healthy blood donors were used to determine clinical sensitivity

282 Prospective samples were collected from 1004 blood donors who called their donation center within 3 d

283 and class II genes in 231 Chinese voluntary blood donors who had cleared HCV infection spontaneously

284 ood mononuclear cells (PBMC) of seropositive blood donors who had spontaneously or therapeutically cl

285 hese autoantibodies and rheumatoid factor in blood donors who later developed rheumatoid arthritis.

286 lopment and persistence were investigated in blood donors who made WNV RNA-positive (viremic) donatio

287 ence T-cell activation in seven of the eight blood donors who responded strongly to wild-type P99beta

288 A total of 738 volunteer blood donors who were positive for anti-hepatitis C viru

289 We have identified five blood donors whose basophils lack detectable levels of t

290 ment and retainment of future generations of blood donors will be needed, and care will be necessary

291 Here, we show that in 32 blood donors with acute WNV infection, Tregs expanded si

292 Physicians may encounter blood donors with adverse events and should be familiar

293 pective cohort study among initially healthy blood donors with an index T cruzi-seropositive donation

294 l blood mononuclear cells (PBMC) from normal blood donors with and without a monoclonal antibody to I

295 varicella-zoster virus infection, we tested blood donors with different CCR5-Delta32 genotypes for v

296 ion of macrophages from patients and healthy blood donors with genetic variants in NLRP3 and CARD8 an

297 Among blood donors with normal hemoglobin levels, low-dose iro

298 Samples from blood donors with resolved and chronic HCV infections ha

299 bout a 20% decrease in reactions among young blood donors, with the greatest benefit observed among t

300 rols, we obtained serum from 101 sex-matched blood donors within the same age range.